Liposomal amphotericin B as a treatment for human leishmaniasis
Top Cited Papers
Open Access
- 20 November 2012
- journal article
- review article
- Published by Informa Healthcare in Emerging Drugs
- Vol. 17 (4), 493-510
- https://doi.org/10.1517/14728214.2012.748036
Abstract
Introduction: Leishmaniasis is a parasitic disease transmitted by phlebotomine sandflies. Between 700,000 and 1.2 million cases of cutaneous leishmaniasis and between 200,000 and 400,000 cases of visceral leishmaniasis (VL), which is fatal if left untreated, occur annually worldwide. Liposomal amphotericin B (LAMB), alone or in combination with other drugs, has been extensively studied as VL treatment, but data on routine field use are limited, and several challenges to patients' access to this life-saving drug remain. Areas covered: This article provides a review of clinical studies on LAMB for VL and other forms of leishmaniasis. The current development of generic versions of LAMB and related challenges are also discussed. Expert opinion: LAMB proved to be highly efficacious and safe in over 8000 VL patients treated by MÉdecins Sans Frontières in South Asia, and its use was feasible even at primary healthcare level. Despite requiring higher doses, LAMB is the drug of choice to treat vulnerable groups (e.g., pregnant or HIV positive) and relapsing VL patients in East Africa. LAMB should be included in national VL guidelines and registered in all VL endemic countries. Its cost should be further reduced and regulatory pathways to prove bioequivalence for generic LAMB products should be implemented.Keywords
This publication has 64 references indexed in Scilit:
- Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelersJournal of the American Academy of Dermatology, 2012
- Limited Effectiveness of High-Dose Liposomal Amphotericin B (AmBisome) for Treatment of Visceral Leishmaniasis in an Ethiopian Population With High HIV PrevalenceClinical Infectious Diseases, 2011
- A Curative Immune Profile One Week after Treatment of Indian Kala-Azar Patients Predicts Success with a Short-Course Liposomal Amphotericin B TherapyPLoS Neglected Tropical Diseases, 2010
- Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?Cancer Chemotherapy and Pharmacology, 2010
- Cutaneous leishmaniasisThe Lancet Infectious Diseases, 2007
- A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experienceJournal of Antimicrobial Chemotherapy, 2004
- Sodium stibogluconate cardiotoxicity and safety of genericsTransactions of the Royal Society of Tropical Medicine and Hygiene, 2003
- Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.The American Journal of Tropical Medicine and Hygiene, 2002
- Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.1998
- Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trialQJM: An International Journal of Medicine, 1994